SCHEMBL5582995

SCHEMBL5582995

CC(C)(C)OC(=O)N1CCCC(C(O)c2ccc(NC(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPN6 P29350 1/20 0.48
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
THRB P10828 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
USP30 Q70CQ3 2/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
HTT P42858 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ABL1 P00519 1/20 0.45
RIN1 Q13671 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
CNR1 P21554 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582931 0.86 HSD11B1 (0.47) ALDH1A1HSD11B1
SCHEMBL5582627 0.84 PTPN2 (0.53) PTPN2PTPN1PTPN6MAPTTP53
SCHEMBL5582918 0.82 HTT (0.49) PTPN2PTPN1PTPN6MAPTTP53
SCHEMBL502899 0.79 TP53 (0.59) PTPN2PTPN1PTPN6MAPTTP53
SCHEMBL502898 0.79 TP53 (0.59) PTPN2PTPN1PTPN6MAPTTP53
SCHEMBL2069130 0.79 MEN1 (0.47) PTPN2PTPN1PTPN6MAPTMEN1
SCHEMBL14454767 0.78 NAMPT (0.59) PTPN2PTPN1PTPN6MAPTTP53
SCHEMBL5705764 0.77 ALDH1A1 (0.46) MAPTMEN1KMT2AUSP30NPC1
SCHEMBL3325441 0.77 USP30 (0.53) MAPTMEN1KMT2AUSP30NPC1
SCHEMBL12631529 0.77 USP30 (0.53) MAPTMEN1KMT2AUSP30NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-7115750-B1 Melanin concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
EP-1218336-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2002-07-03 EP disclosed
WO-2001021577-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173498-A1 Melanin concentrating hormone antagonist MC1R, MCHR1, MCHR2 PTPN2 637/4885PTPN1 285/4885PTPN6 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.